🔗 Share this article

Given that the US continues making sweeping adjustments to its vaccine guidelines, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 shots throughout the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her short position at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities had intended to announce radical changes to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US at odds with many the global community with insufficient data for improved outcomes. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US so as to align more like the Danish model, a nation with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Background

Høeg has little discernible background in drug development, oversight or administrative roles, which has been standard for previous directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for leading the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that former directors who ran the center have had.”

This division has an vast range of responsibilities at the FDA, she stated.

“Everybody just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be supervised,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major leadership component to the job, which manages over 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” the former official said.

Agency Reaction and Disputed Programs

In response to inquiries about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “questions are based on flawed premises”.

“Her resume is consistent with the duties of her role,” the representative stated, citing the months Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s new expedited review system, a controversial expedited therapy clearance system that apparently concerned her preceding directors. “How are these therapies being picked for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards laxer rules of most medications, with the exception of shots.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, track record, critics observe. She released a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new federal leadership encompassed changing rules for recently developed shots and discontinuing “optional” immunizations, she said after the election on a audio program. At the FDA, Høeg has allegedly proposed preventing adolescent males from obtaining Covid vaccines.

“She is an all-around dogmatist who starts off with her preconceived notions and tailors the evidence to fit the evidence in a highly deceptive, untruthful fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|